Sage Therapeutics, Inc.
SAGE
$6.72
-$0.035-0.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.04% | -2.38% | 9.04% | 5.19% | -231.69% |
| Total Depreciation and Amortization | -13.18% | -49.41% | -18.01% | -7.44% | -17.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.27% | -31.20% | -19.90% | 24.73% | -36.42% |
| Change in Net Operating Assets | -222.53% | 1,862.14% | -116.86% | -87.99% | 154.75% |
| Cash from Operations | -22.79% | 19.19% | -2.40% | -112.62% | 68.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.70% | -42.54% | 21,098.45% | -100.28% | 232.39% |
| Cash from Investing | -1.70% | -42.54% | 21,098.45% | -100.28% | 231.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -82.46% | 425.27% | -- |
| Repurchase of Common Stock | -4,600.00% | 99.50% | -39,800.00% | 50.00% | 99.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 7,500.00% | -100.19% | -87.15% | 418.37% | 694.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -79.09% | -7,194.89% | 99.62% | -170.52% | 232.73% |